Top Page
Werewolf Therapeutics
(NASDAQ:HOWL)
Werewolf Therapeutics (HOWL) vs. SPDR S&P 500 ETF (SPY)
Werewolf Therapeutics Business Overview & Revenue Model
Werewolf Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -49.00K | 1.89M | 19.94M | 16.40M | 0.00 | 0.00 |
| Gross Profit | -1.80M | 71.00K | 18.18M | 13.89M | -735.00K | -777.00K |
| EBITDA | -51.37M | -64.05M | -32.47M | -51.30M | -49.25M | -14.26M |
| Net Income | -72.84M | -70.52M | -37.37M | -53.81M | -49.77M | -14.94M |
Balance Sheet | ||||||
| Total Assets | 79.63M | 126.93M | 174.83M | 160.25M | 179.25M | 96.40M |
| Cash, Cash Equivalents and Short-Term Investments | 66.61M | 111.00M | 134.34M | 129.31M | 157.53M | 92.57M |
| Total Debt | 9.64M | 37.09M | 51.92M | 14.68M | 15.66M | 2.54M |
| Total Liabilities | 50.01M | 53.54M | 63.46M | 37.91M | 26.46M | 148.26M |
| Stockholders Equity | 29.61M | 73.39M | 111.37M | 122.34M | 152.79M | -51.86M |
Cash Flow | ||||||
| Free Cash Flow | -63.64M | -56.44M | -33.38M | -44.21M | -43.37M | -19.18M |
| Operating Cash Flow | -63.52M | -56.19M | -32.61M | -40.60M | -42.88M | -18.62M |
| Investing Cash Flow | -123.00K | -254.00K | -769.00K | -3.61M | -498.00K | -560.00K |
| Financing Cash Flow | 6.21M | 13.08M | 58.43M | 15.91M | 109.43M | 93.86M |
Werewolf Therapeutics Technical Analysis
Werewolf Therapeutics Risk Analysis
Werewolf Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $64.95M | -2.69 | -54.21% | ― | -19.44% | -492.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $65.13M | -1.22 | ― | ― | ― | 18.51% | |
41 Neutral | $55.33M | -0.74 | -100.55% | ― | -100.00% | -22.09% | |
28 Underperform | $78.83M | -0.62 | -50.68% | ― | ― | 73.18% |
Werewolf Therapeutics Corporate Events
Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics to stimulate the immune system for cancer treatment, operating primarily in the biotechnology sector.
Werewolf Therapeutics, Inc. is conducting a clinical study titled A Phase 1b/2 Multisite Dose- and Regimen-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, and antitumor activity of WTX-330, a novel drug, in adult patients with advanced solid tumors or lymphoma. Key objectives include determining the maximum tolerated dose and assessing the drug’s impact on overall survival and immunological biomarkers.
Werewolf Therapeutics, Inc. (HOWL) is conducting a Phase I/Ib clinical study titled A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors. The study aims to evaluate the safety and efficacy of WTX-124, both alone and in combination with pembrolizumab, in treating advanced or metastatic solid tumors. This research is significant as it explores new treatment avenues for challenging cancer types.
Werewolf Therapeutics announced the passing of Dr. Alon Lazarus, a Board member, on September 30, 2025. His death left the company’s Audit Committee noncompliant with Nasdaq’s listing rules, prompting the company to plan for appointing a new independent director to regain compliance.
The most recent analyst rating on (HOWL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Werewolf Therapeutics stock, see the HOWL Stock Forecast page.
Werewolf Therapeutics, Inc. faces significant business risks due to potential disruptions at the FDA and other government agencies stemming from funding cuts, personnel losses, and regulatory reforms. The recent reduction in force and budget cuts at the FDA, along with executive orders from the Trump administration, could delay the guidance and approval processes critical for the company’s clinical development programs. Such disruptions may hinder the timely development and approval of Werewolf’s product candidates, negatively impacting their business operations. Additionally, government shutdowns and public health emergencies could further exacerbate these challenges, affecting the company’s ability to secure necessary capital and continue its operations.
Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics that stimulate the immune system to treat cancer and other immune-mediated conditions, operating primarily in the biotechnology sector. In its latest earnings report for the quarter ending June 30, 2025, Werewolf Therapeutics highlighted its ongoing efforts in research and development, despite facing significant financial challenges. The company reported a net loss of $17.98 million for the quarter, with total operating expenses amounting to $17.54 million, primarily driven by research and development costs. Werewolf Therapeutics ended the quarter with $77.6 million in cash and cash equivalents, a decrease from $110.99 million at the end of 2024, indicating a need for additional funding to continue its operations and development programs. Looking ahead, Werewolf Therapeutics remains committed to advancing its product candidates through clinical trials and exploring strategic partnerships to support its financial needs, while navigating the competitive landscape of the biotechnology industry.
Werewolf Therapeutics reported its second-quarter 2025 financial results and provided a business update, highlighting progress in their clinical trials and product development. The company is on track for an interim data readout of its WTX-124 Phase 1/1b trial in late 2025, targeting melanoma and renal cell carcinoma. They also plan to engage with the FDA regarding potential pathways for WTX-124. Additionally, Werewolf introduced WTX-1011, a new T-cell engager candidate for prostate cancer, and announced plans to nominate another candidate by year-end. Financially, the company reported a net loss of $18 million for the quarter, with sufficient cash to fund operations into late 2026.
The most recent analyst rating on (HOWL) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Werewolf Therapeutics stock, see the HOWL Stock Forecast page.